Key statistics
As of last trade Avacta Group PLC (RTQ1:FRA) traded at 0.74, -18.68% below its 52-week high of 0.91, set on Dec 02, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.74 |
|---|---|
| High | 0.74 |
| Low | 0.74 |
| Bid | 0.705 |
| Offer | 0.78 |
| Previous close | 0.705 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 440.42m |
| Free float | 426.19m |
| P/E (TTM) | -- |
| Market cap | 297.28m GBP |
| EPS (TTM) | -0.0891 GBP |
Data delayed at least 15 minutes, as of Mar 02 2026 07:10 GMT.
More ▼
Announcements
- PreCISION payload delivery advantage over ADC
- Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
- Avacta to Participate in Conference March 2026
- Appointment of CSO
- Avacta appoints Francis Wilson as Chief Scientific Officer
- Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
- Faridoxorubicin Program Clinical Updates
- Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
- FDA Clearance of IND Application for AVA6103
- Avacta Announces Year-end Trading Update
More ▼
